Group 1 - The core viewpoint of the article highlights that Kangchen Pharmaceutical (01681) has seen a significant stock price increase, rising over 7% to reach a new high of 19.49 HKD, with a trading volume of 31.34 million HKD [1] - On February 13, the Hang Seng Index Company announced that Kangchen Pharmaceutical will be included in the Hang Seng Composite Index as of December 31, 2025, with changes effective after market close on March 6, 2026, and starting from March 9, 2026 [1] - According to a report from CICC, Kangchen Pharmaceutical is likely to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] Group 2 - The company announced a new share buyback plan, adding up to 100 million HKD to the previously authorized buyback, bringing the total planned expenditure for share repurchases to no more than 300 million HKD [1] - The board of directors expresses confidence in the company's business development and future prospects, believing that the current stock price does not fully reflect its intrinsic value and long-term growth potential [1]
港股异动 | 康臣药业(01681)涨超7%创新高 获纳入恒生综合指数 机构料其有望入通